# Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors

> **NCT01065623** · PHASE1 · TERMINATED · sponsor: **Bayer** · enrollment: 2 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** BAY79-4620

## Key facts

- **NCT ID:** NCT01065623
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-04
- **Primary completion:** 2010-08
- **Final completion:** 2010-08
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was terminated due to safety reasons
- **Last updated:** 2014-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01065623

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01065623, "Clinical Study to Evaluate the Maximum Tolerated Dose of BAY79-4620 Given Every 2 Weeks to Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01065623. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*